well as research on primary prevention. Much of the global disease burden arises from smoking (about 6·2 million deaths and 144 million disability-adjusted life-years [DALYs]), excessive salt intake (3·7 million deaths and 74·3 million DALYs), sugar (0·1 million deaths and 6·2 million DALYs), and alcohol (2·8 million deaths and 99·3 million DALYs). Increasing public awareness of the harms of these risk factors could contribute to improved individual and community-driven self-management of lifestyle behaviours. Reduction of exposure to these risk factors at a population level (for example, reducing salt and sugar content in processed foods at the manufacturing stage) has been shown to be beneficial for cardiovascular disease and overall health. Compelling evidence shows that taxation on these hazardous behavioural factors could represent a valuable strategy to improve health. Revenue from these taxations could and should be used to fund primary preventive programmes and research on stroke and other major non-communicable diseases.

A 2012 resolution from the UN has mandated for all governments to achieve a 25% reduction in the burden of stroke from stroke and other non-communicable diseases by 2025. Cost-savings from the reduction of the burden of stroke and other non-communicable diseases could then be re-invested in health and other social programmes to fund primary prevention research and develop and implement sustainable evidence-based primary prevention strategies in their communities. Supported by non-government organisations and the health sector, as well as communities, industries, and individuals at risk for stroke or non-communicable diseases, these preventive programmes could slow down, stop, and eventually revert the stroke or non-communicable disease epidemics. We have heard the calls for actions about primary prevention. Now is the time for governments, health organisations, and individuals to proactively reduce the global burden of stroke. Governments of all countries should develop and implement an emergency action plan for the primary prevention of stroke.

Valery L Feigin, Rita Krishnamurthi
National Institute for Stroke and Applied Neurosciences, School of Public Health and Psychosocial Studies, Faculty of Health and Environmental Sciences, University of Technology, Northcote, Auckland 0627, New Zealand
valery.feigin@aut.ac.nz

We declare no competing interests.

8 Wilson N. Salt tax could reduce population’s salt intake. BMJ 2004; 329: 918.

Concurrent with the global increase in obesity, numerous studies and reviews have been published concerning associations of overweight and obesity with mortality. Their findings have prompted considerable public health debate. There is ongoing discussion as to whether cutoff points for body-mass index (BMI) categories should differ across regions or racial or ethnic groups. Additionally, studies differ in their assessment of the relation between BMI and mortality. In particular, BMI in the overweight category (BMI 25–30 kg/m²) is not consistently associated
with increased mortality. To improve precision, observational studies have been combined in pooled analyses and meta-analyses. Pooled analyses benefit from the use of harmonised methods but, unlike meta-analyses, are not generally based on systematic review.

In *The Lancet*, The Global BMI Mortality Collaboration presents results from the largest ever pooled dataset about the relation between BMI and mortality. Their data began with 239 studies, in 32 countries, with more than 10 million participants and about 1.6 million deaths. Prespecified analyses of never smokers without pre-existing chronic disease, excluding the first 5 years of follow-up, are presented for about 3.9 million participants and about 386,000 deaths occurring in 189 studies. This study is notable for the use of standardised methods to extract hazard ratios (HRs) for mortality across the studies and for extensive and valuable appendices that examine diverse subsets of the pooled data. The authors made efforts to address reverse causation and residual confounding. Results are broadly similar to other recent studies. For example, HRs were J-shaped, with increased risk of mortality for both low BMI and obesity (BMI ≥30 kg/m²). This study documents heterogeneity in the association between BMI and mortality across different continents and shows weaker associations in older populations, especially in those aged 70 years and older. For overweight adults (BMI 25–<30 kg/m²), HRs—adjusting for age and sex and excluding individuals with baseline chronic disease—ranged from 0.99 (95% CI 0.98–1.00) after adjustment for smoking to 1.11 (1.10–1.11) after exclusion of ever smokers and the first 5 years of follow-up. The elevated HR of 1.11 in overweight adults after exclusion of about 60% of the sample and about 75% of deaths is a key result of this pooled analysis.

Two major issues are raised by this important paper. The first is whether conclusions about the relation between BMI and mortality from analyses with extensive exclusions can be generalisable and unbiased. The second is what sort of public health guidance can be obtained from analyses that pool global data. Substantial research and conceptual questions remain for each of these issues. Samples of different distributions of environmental and person-specific factors (eg, disease history, diet, and physical activity) are difficult to address consistently in large pooling studies. Exclusion of ever smokers, deaths in the first 5 years of follow-up, and pre-existing chronic disease (where available) might further increase these differences. Extensive exclusions might also limit the generalisability of resulting health recommendations. Selection bias and early mortality exclusion, to control for potential bias from weight change due to occult disease leading to reverse causation, pose additional challenges for inference from pooling studies. For example, Monte Carlo simulation and analytical analyses of the association between BMI and mortality indicate that exclusion of 2 years or 5 years of early mortality does not necessarily reduce bias and can even increase bias of estimated HRs.

Challenges in deriving global public health recommendations are unlikely to be resolved by ever-larger datasets without further developments in study data and design. New study designs such as mendelian randomisation, new data elements such as weight histories, and increased attention to BMI over the life course, might improve our understanding of the links between excess bodyweight and mortality. The present study compares data from four continents, pooling data across diverse racial and ethnic groups, and across countries with very different patterns of chronic disease management. Large studies of specific race and ethnic groups, such as that of Yi and colleagues of 12.8 million Koreans, can help to clarify recommendations for specific countries or demographic groups even if these studies cannot conclusively address the limits of observational studies. Despite the limitations of observational studies for causal inference of obesity and mortality, many crucial questions about BMI will continue to rely on
observational randomised trials. To date, few sufficiently sized randomised trials have been done to address whether weight-loss interventions reduce mortality or morbidity. One trial was ended after about 10 years of follow-up because no association between weight loss and cardiovascular events was found. Weight-loss interventions have only modest long-term effectiveness and generally target behaviours, such as diet and physical activity, that can lead to change in BMI rather than directly targeting BMI itself. Therefore, clinical trials are limited in their capacity to address causal relations between BMI and mortality.

**Important challenges remain in the effort to translate epidemiological evidence of excess bodyweight and mortality into effective guidelines and public health interventions.** The Lancet, via the World Obesity Federation, and other coalitions such as the US National Collaborative on Childhood Obesity Research, are championing diverse approaches to this challenge including support for better measurement, systems models, and increased attention to the evaluation of obesity-related policies.

“David Berrigan, Richard P Troiano, Barry I Graubard Division of Cancer Control and Population Sciences (DB, RPT) and Division of Cancer Epidemiology and Genetics (BIG), National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA berrigad@mail.nih.gov

We declare no competing interests. This Comment is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health.

**Age of PISCES: stem-cell clinical trials in stroke**

Laboratory studies and limited clinical trials over the past two decades have shown feasibility and safety, and have revealed potential mechanisms of action of stem-cell therapy in ischaemic stroke. Despite consistent efficacy in animal studies, functional benefits after transplantation of stem cells remain to be shown unequivocally in stroke patients. Translation of stem-cell therapy from the laboratory to the clinic has been approached with ample caution, in part due to the largely negative outcomes for several stroke therapeutics in human beings compared with those in animals. Negative results in clinical trials of stem-cell therapy for stroke could put regenerative medicine in this area in jeopardy, as for Parkinson’s disease when patients given transplanted fetal cells had controversial adverse events.

Strict adherence to the preclinical findings when designing clinical trials might facilitate translation of outcomes with stem-cell therapy to the clinic. To this end, laboratory studies support the concepts of neuroprotection for the acute phase of stroke and neuroregeneration via stem-cell therapy for the subacute and chronic stages. Subacute delivery of stem cells is designed to sequester early secondary cell death, for instance by suppressing oxidative stress, inflammation, and...